Advertisement

Converting-Enzyme Inhibition in the Management of Patients with Severe Chronic Congestive Heart Failure

  • M. Packer
Conference paper

Abstract

Although converting-enzyme inhibition has become an established approach to the treatment of patients with severe chronic heart failure [4], it is not clear how clinicians should identify patients who are likely to benefit from treatment with these drugs. Can pretreatment hemodynamic variables predict response? Can the initial effect of treatment predict long-term efficacy? Can hormonal variables predict clinical benefits? In this chapter we shall address these important issues.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bussmann W-D, Loehner J, Kaltenbach M (1977) Orally administered isosorbide dinitrate in patients with and without left ventricular failure due to acute myocardial infarction. Am J Cardiol 39: 91–96PubMedCrossRefGoogle Scholar
  2. 2.
    Massie B, Kramer BL, Topic N (1984) Lack of relationship between short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation 69: 1135–1141PubMedCrossRefGoogle Scholar
  3. 3.
    Miller RR, Vismara LA, Zelis R, Amsterdam EA, Mason DT (1975) Clinical use of sodium nitro- prusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volumes, pump and mechanical performance. Circulation 51: 328–336PubMedGoogle Scholar
  4. 4.
    Packer M (1983) Vasodilator and inotropic therapy for severe chronic heart failure: passion and skepticism. J Am Coll Cardiol 2: 841–852PubMedCrossRefGoogle Scholar
  5. 5.
    Packer M (1985) Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure: the price we pay for interfering with evolution. J Am Coll Cardiol 6: 171–173CrossRefGoogle Scholar
  6. 6.
    Packer M, Meller J, Medina N, Gorlin R, Herman MV (1980) Importance of left ventricular chamber size in determining the response to hydralazine in severe chronic heart failure. N Engl J Med 303: 250–255PubMedCrossRefGoogle Scholar
  7. 7.
    Packer M, Medina N, Yushak M, Meller J (1983) Hemodynamic patterns of response during longterm captopril therapy for severe chronic heart failure. Circulation 68: 803–812PubMedCrossRefGoogle Scholar
  8. 8.
    Packer M, Medina N, Yushak M (1984) Relation between serum sodium concentration and the hemodynamic and clinical responses to converting-enzyme inhibition with captopril in severe heart failure. J Am Coll Cardiol 3: 1035–1043PubMedCrossRefGoogle Scholar
  9. 9.
    Packer M, Medina N, Yushak M (1984) Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med 100: 782–789PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • M. Packer
    • 1
  1. 1.Division of CardiologyThe Mount Sinai Medical CenterNew YorkUSA

Personalised recommendations